MYALEPT
Total Payments
$2.5M
Transactions
2,786
Doctors
936
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $722,817 | 651 | 207 |
| 2023 | $561,152 | 347 | 156 |
| 2022 | $321,206 | 302 | 74 |
| 2021 | $154,474 | 349 | 202 |
| 2020 | $131,351 | 187 | 55 |
| 2019 | $292,017 | 318 | 118 |
| 2018 | $259,821 | 212 | 142 |
| 2017 | $101,104 | 420 | 202 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9M | 1,164 | 76.1% |
| Grant | $259,636 | 10 | 10.2% |
| Consulting Fee | $179,281 | 54 | 7.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $64,592 | 38 | 2.5% |
| Food and Beverage | $37,922 | 1,379 | 1.5% |
| Travel and Lodging | $35,102 | 125 | 1.4% |
| Space rental or facility fees (teaching hospital only) | $14,900 | 8 | 0.6% |
| Honoraria | $9,492 | 6 | 0.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,440 | 2 | 0.3% |
Payments by Type
Research
$1.9M
1,164 transactions
General
$608,365
1,622 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL) | Chiesi USA, Inc. | $431,994 | 0 |
| A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial Lipodystrophy | Amryt Pharma Holdings Ltd | $425,543 | 0 |
| A 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily SC Metreleptin Treatment in Patients With Generalized Lipodystrophy | Amryt Pharma Holdings Ltd | $231,254 | 0 |
| MEASuRE: Metreleptin Effectiveness And Safety Registry | Amryt Pharma Holdings Ltd | $186,422 | 0 |
| Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy | Chiesi USA, Inc. | $145,400 | 0 |
| NOT AVAILABLE | Aegerion Pharmaceuticals, Inc. | $135,194 | 1 |
| PMR 4 | Aegerion Pharmaceuticals, Inc. | $110,962 | 1 |
| MEASuRE | Aegerion Pharmaceuticals, Inc. | $73,356 | 10 |
| Clinical impact of anti-drug and neutralizing antibodies against metreleptin in patients with partial lipodystrophy | Amryt Pharma Holdings Ltd | $64,305 | 0 |
| MEASuRE: Metreleptin Effectiveness And Safety Registry (MEASuRE) | Chiesi USA, Inc. | $55,656 | 3 |
| Metreleptin Effectiveness And Safety Registry | Amryt Pharma Holdings Ltd | $52,135 | 0 |
| Clinical impact of anti-drug and neutralizing antibodies against metreleptin in patients with partial lipodystrophy (HUM00196087) | Amryt Pharma Holdings Ltd | $21,435 | 0 |
| UNKNOWN | Aegerion Pharmaceuticals, Inc. | $1,922 | 1 |
Top Doctors Receiving Payments for MYALEPT — Page 38
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Jeffrey Fajardo | — | Topeka, KS | $11.11 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Cleveland, OH | $11.11 | 1 |
| , MSN, FNP-BC | Family | Westlake, OH | $11.11 | 1 |
| , D.O | Family Medicine | Westlake, OH | $11.11 | 1 |
| , MD | Internal Medicine | Westlake, OH | $11.11 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Wilmington, NC | $11.00 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Saint Louis, MO | $10.92 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Wheeling, WV | $10.86 | 1 |
| , M.D | Family Medicine | Elkhart, IN | $10.74 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Maryville, IL | $10.71 | 1 |
| , MD | Pediatrics | Louisville, KY | $10.57 | 1 |
| , M.D | Pediatric Endocrinology | Louisville, KY | $10.57 | 1 |
Ad
Manufacturing Companies
- Amryt Pharma Holdings Ltd $1.2M
- Chiesi USA, Inc. $722,817
- Aegerion Pharmaceuticals, Inc. $652,942
Product Information
- Type Drug
- Total Payments $2.5M
- Total Doctors 936
- Transactions 2,786
About MYALEPT
MYALEPT is a drug associated with $2.5M in payments to 936 healthcare providers, recorded across 2,786 transactions in the CMS Open Payments database. The primary manufacturer is Amryt Pharma Holdings Ltd.
Payment data is available from 2017 to 2024. In 2024, $722,817 was paid across 651 transactions to 207 doctors.
The most common payment nature for MYALEPT is "Unspecified" ($1.9M, 76.1% of total).
MYALEPT is associated with 13 research studies, including "Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL)" ($431,994).